Zenas BioPharma Etf Forward View
| ZBIO Etf | USD 20.88 0.59 2.75% |
Zenas Etf outlook is based on your current time horizon.
As of today, the RSI of Zenas BioPharma's share price is approaching 42. This usually means that the etf is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Zenas BioPharma, making its price go up or down. Momentum 42
Sell Extended
Oversold | Overbought |
EPS Estimate Next Quarter (0.73) | EPS Estimate Current Year (5.34) | EPS Estimate Next Year (4.40) | Wall Street Target Price 43.5714 | EPS Estimate Current Quarter (0.85) |
Using Zenas BioPharma hype-based prediction, you can estimate the value of Zenas BioPharma Common from the perspective of Zenas BioPharma response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Zenas BioPharma using Zenas BioPharma's stock options and short interest. It helps to benchmark the overall future attitude of investors towards Zenas using crowd psychology based on the activity and movement of Zenas BioPharma's stock price.
Zenas BioPharma Implied Volatility | 2.16 |
Zenas BioPharma's implied volatility exposes the market's sentiment of Zenas BioPharma Common stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Zenas BioPharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Zenas BioPharma stock will not fluctuate a lot when Zenas BioPharma's options are near their expiration.
The Naive Prediction forecasted value of Zenas BioPharma Common on the next trading day is expected to be 28.32 with a mean absolute deviation of 2.88 and the sum of the absolute errors of 178.41. Zenas BioPharma after-hype prediction price | USD 20.88 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as etf price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Zenas BioPharma to cross-verify your projections. Prediction based on Rule 16 of the current Zenas contract
Based on the Rule 16, the options market is currently suggesting that Zenas BioPharma Common will have an average daily up or down price movement of about 0.14% per day over the life of the 2026-03-20 option contract. With Zenas BioPharma trading at USD 20.88, that is roughly USD 0.0282 . If you think that the market is fully incorporating Zenas BioPharma's daily price movement you should consider acquiring Zenas BioPharma Common options at the current volatility level of 2.16%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Open Interest Against 2026-03-20 Zenas Option Contracts
Although open interest is a measure utilized in the options markets, it could be used to forecast Zenas BioPharma's spot prices because the number of available contracts in the market changes daily, and new contracts can be created or liquidated at will. Since open interest in Zenas BioPharma's options reflects these daily shifts, investors could use the patterns of these changes to develop long and short-term trading strategies for Zenas BioPharma stock based on available contracts left at the end of a trading day.
Please note that to derive more accurate forecasting about market movement from the current Zenas BioPharma's open interest, investors have to compare it to Zenas BioPharma's spot prices. As Ford's stock price increases, high open interest indicates that money is entering the market, and the market is strongly bullish. Conversely, if the price of Zenas BioPharma is decreasing and there is high open interest, that is a sign that the bearish trend will continue, and investors may react by taking short positions in Zenas. So, decreasing or low open interest during a bull market indicates that investors are becoming uncertain of the depth of the bullish trend, and a reversal in sentiment will likely follow.
Zenas BioPharma Additional Predictive Modules
Most predictive techniques to examine Zenas price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Zenas using various technical indicators. When you analyze Zenas charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Zenas BioPharma Naive Prediction Price Forecast For the 31st of January
Given 90 days horizon, the Naive Prediction forecasted value of Zenas BioPharma Common on the next trading day is expected to be 28.32 with a mean absolute deviation of 2.88, mean absolute percentage error of 16.40, and the sum of the absolute errors of 178.41.Please note that although there have been many attempts to predict Zenas Etf prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Zenas BioPharma's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Zenas BioPharma Etf Forecast Pattern
| Backtest Zenas BioPharma | Zenas BioPharma Price Prediction | Buy or Sell Advice |
Zenas BioPharma Forecasted Value
In the context of forecasting Zenas BioPharma's Etf value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Zenas BioPharma's downside and upside margins for the forecasting period are 18.89 and 37.75, respectively. We have considered Zenas BioPharma's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Zenas BioPharma etf data series using in forecasting. Note that when a statistical model is used to represent Zenas BioPharma etf, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 122.7454 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 2.8776 |
| MAPE | Mean absolute percentage error | 0.1144 |
| SAE | Sum of the absolute errors | 178.409 |
Predictive Modules for Zenas BioPharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Zenas BioPharma Common. Regardless of method or technology, however, to accurately forecast the etf market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the etf market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Zenas BioPharma After-Hype Price Density Analysis
As far as predicting the price of Zenas BioPharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Zenas BioPharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Etf prices, such as prices of Zenas BioPharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Zenas BioPharma Estimiated After-Hype Price Volatility
In the context of predicting Zenas BioPharma's etf value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Zenas BioPharma's historical news coverage. Zenas BioPharma's after-hype downside and upside margins for the prediction period are 11.53 and 30.23, respectively. We have considered Zenas BioPharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Zenas BioPharma is slightly risky at this time. Analysis and calculation of next after-hype price of Zenas BioPharma Common is based on 3 months time horizon.
Zenas BioPharma Etf Price Outlook Analysis
Have you ever been surprised when a price of a ETF such as Zenas BioPharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Zenas BioPharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Etf price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Zenas BioPharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.11 | 9.43 | 0.00 | 0.01 | 10 Events / Month | 7 Events / Month | In about 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
20.88 | 20.88 | 0.00 |
|
Zenas BioPharma Hype Timeline
Zenas BioPharma Common is at this time traded for 20.88. The entity stock is not elastic to its hype. The average elasticity to hype of competition is -0.01. Zenas is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is at this time at -0.11%. %. The volatility of related hype on Zenas BioPharma is about 8896.23%, with the expected price after the next announcement by competition of 20.87. About 26.0% of the company outstanding shares are owned by insiders. The company recorded earning per share (EPS) of 13.67. Zenas BioPharma Common had 1:2 split on the 24th of May 2018. Given the investment horizon of 90 days the next forecasted press release will be in about 10 days. Check out Historical Fundamental Analysis of Zenas BioPharma to cross-verify your projections.Zenas BioPharma Related Hype Analysis
Having access to credible news sources related to Zenas BioPharma's direct competition is more important than ever and may enhance your ability to predict Zenas BioPharma's future price movements. Getting to know how Zenas BioPharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Zenas BioPharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| UPB | Upstream Bio | (1.45) | 9 per month | 3.40 | 0.13 | 7.87 | (5.24) | 24.37 | |
| NTLA | Intellia Therapeutics | 0.73 | 7 per month | 0.00 | (0.08) | 10.12 | (8.64) | 42.23 | |
| SNDX | Syndax Pharmaceuticals | (0.13) | 20 per month | 2.36 | 0.13 | 8.70 | (3.59) | 18.37 | |
| WVE | Wave Life Sciences | 0.45 | 8 per month | 4.04 | 0.1 | 8.92 | (6.68) | 164.47 | |
| RLAY | Relay Therapeutics | (0.16) | 20 per month | 3.39 | 0.05 | 6.11 | (5.45) | 27.25 | |
| NVAX | Novavax | 0.04 | 9 per month | 2.95 | 0.04 | 6.10 | (5.54) | 26.68 | |
| AMLX | Amylyx Pharmaceuticals | 0.08 | 9 per month | 3.11 | 0.01 | 8.11 | (5.24) | 20.49 | |
| ORIC | Oric Pharmaceuticals | (0.07) | 9 per month | 0.00 | (0.05) | 6.63 | (4.48) | 15.34 | |
| TRVI | Trevi Therapeutics | (0.41) | 9 per month | 3.25 | 0.0005 | 6.73 | (5.94) | 25.67 | |
| INBX | Inhibrx Biosciences | (0.14) | 11 per month | 2.82 | 0.15 | 7.03 | (5.44) | 112.80 |
Other Forecasting Options for Zenas BioPharma
For every potential investor in Zenas, whether a beginner or expert, Zenas BioPharma's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Zenas Etf price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Zenas. Basic forecasting techniques help filter out the noise by identifying Zenas BioPharma's price trends.Zenas BioPharma Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Zenas BioPharma etf to make a market-neutral strategy. Peer analysis of Zenas BioPharma could also be used in its relative valuation, which is a method of valuing Zenas BioPharma by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Zenas BioPharma Market Strength Events
Market strength indicators help investors to evaluate how Zenas BioPharma etf reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Zenas BioPharma shares will generate the highest return on investment. By undertsting and applying Zenas BioPharma etf market strength indicators, traders can identify Zenas BioPharma Common entry and exit signals to maximize returns.
| Accumulation Distribution | 48294.12 | |||
| Daily Balance Of Power | (0.26) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 21.56 | |||
| Day Typical Price | 21.33 | |||
| Price Action Indicator | (0.98) | |||
| Period Momentum Indicator | (0.59) | |||
| Relative Strength Index | 42.24 |
Zenas BioPharma Risk Indicators
The analysis of Zenas BioPharma's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Zenas BioPharma's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting zenas etf prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 5.89 | |||
| Semi Deviation | 11.16 | |||
| Standard Deviation | 9.98 | |||
| Variance | 99.58 | |||
| Downside Variance | 133.76 | |||
| Semi Variance | 124.44 | |||
| Expected Short fall | (5.78) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Zenas BioPharma
The number of cover stories for Zenas BioPharma depends on current market conditions and Zenas BioPharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Zenas BioPharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Zenas BioPharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Zenas BioPharma Short Properties
Zenas BioPharma's future price predictability will typically decrease when Zenas BioPharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Zenas BioPharma Common often depends not only on the future outlook of the potential Zenas BioPharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Zenas BioPharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 41.8 M | |
| Cash And Short Term Investments | 350.8 M |
Other Information on Investing in Zenas Etf
Zenas BioPharma financial ratios help investors to determine whether Zenas Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenas with respect to the benefits of owning Zenas BioPharma security.